A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma.

Autor: Embaby A; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Huijberts SCFA; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Wang L; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Leite de Oliveira R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; CEMM, Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Nuijen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Steenis C; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kluin RJC; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lieftink C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Smith CG; NeoGenomics, Babraham Research Park, Cambridge, United Kingdom., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Thienen JV; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Opdam FL; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Beijnen JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Faculty of Science, Utrecht University, Utrecht, the Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Faculty of Science, Utrecht University, Utrecht, the Netherlands., Schellens JHM; Faculty of Science, Utrecht University, Utrecht, the Netherlands., Wilgenhof S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Aug 01; Vol. 30 (15), pp. 3157-3166.

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.

Autor: Huijberts SCFA; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. s.huijberts@nki.nl., van Geel RMJM; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands.; Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands., van Brummelen EMJ; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Centre for Human Drug Research, Leiden, The Netherlands., Opdam FL; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. f.opdam@nki.nl., Marchetti S; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands., Steeghs N; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands., Pulleman S; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands., Thijssen B; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands., Beijnen JH; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Utrecht University, Utrecht, The Netherlands., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute and The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schellens JHM; Utrecht University, Utrecht, The Netherlands.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 May; Vol. 85 (5), pp. 917-930. Date of Electronic Publication: 2020 Apr 09.